PubMed · 2026-05-25
A review of research finds that compounds from cannabis plants may help protect brain function and slow cognitive decline in Parkinson's disease, though current clinical evidence is too limited and inconsistent to support treatment recommendations yet.
The endocannabinoid system — the brain's own cannabinoid signaling network — is a significant regulator of synaptic plasticity and neuroinflammation, both of which are disrupted in Parkinson's disease.
Preclinical (animal model) studies show cannabinoid compounds can preserve neural circuits and reduce neuroinflammation relevant to cognitive decline in Parkinson's disease.
Available human clinical trials are limited, underpowered, and heterogeneous — with cognition typically measured as a secondary outcome — making firm clinical recommendations impossible at this stage.
